Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 2, 2025

Supplemental Figure 2 from Beyond the Promoter: Total MGMT Gene Methylation Modulates Response to DNA-Alkylating Agents in Glioma

View Full Paper
Ask AI
Bookmark
Share

Authors

NBNicole BricenoJJJinkyu JungALAmin Li

Discussion

Loading...

Member takes

Overview

Pathway enrichment analysis reveals differences between carmustine-sensitive and resistant glioma cell lines, suggesting a role of gene methylation.

Key Points

  • Gene methylation status alters the effectiveness of DNA-alkylating agents like carmustine in gliomas, highlighting treatment personalization.
  • Pathway enrichment analysis showed significant differences between carmustine-sensitive and resistant glioma cell lines, supporting tailored therapies.
  • Understanding the relationship between MGMT gene methylation and drug resistance could improve glioma patient outcomes with targeted interventions.
  • Cell line studies provide insight into potential mechanisms of resistance against carmustine, guiding future therapeutic strategies.

Cite This Study

Briceno et al. (2025) studied this question.

synapsesocial.com/papers/68de68f183cbc991d0a219c7https://doi.org/10.1158/1535-7163.30255700
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Supplemental Table 1 from Beyond the Promoter: Total <i>MGMT</i> Gene Methylation Modulates Response to DNA-Alkylating Agents in Glioma2025
  2. 2Supplemental Figure 1 from Beyond the Promoter: Total <i>MGMT</i> Gene Methylation Modulates Response to DNA-Alkylating Agents in Glioma2025
  3. 3Data from Beyond the Promoter: Total <i>MGMT</i> Gene Methylation Modulates Response to DNA-Alkylating Agents in Glioma2025
  4. 4Supplementary Figure S7 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT2024
  5. 5Supplementary Figure S7 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT2024